TFCP2L1

Across TCGA pan-cancer cohorts, TFCP2L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TFCP2L1 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TFCP2L1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TFCP2L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where TFCP2L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	1.000	0.354	.019	14	view →
LUAD	DFS	Quartile	All	1.000	0.267	.010	13	view →
GBM	OS	Quartile	All	0.165	0.625	.017	6	view →
UCEC	DFS	Tertile	III,IV	1.000	0.492	.042	4	view →
HNSC	DFS	Median	III,IV	0.942	0.606	.016	4	view →
LSCC	DFS	Median	II,III,IV	1.000	0.779	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TFCP2L1–CCRCC (OS)

Open the CCRCC breakdown →